{"id":"W4380078644","doi":"10.1002/hon.3163_5","title":"NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; McGill University Health Centre","funders":"National Cancer Institute; Agenzia Italiana del Farmaco, Ministero della Salute; National Institutes of Health; Seagen; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Brentuximab vedotin; Neutropenia; Clinical endpoint; Oncology; Progression-free survival; Phases of clinical research; Randomized controlled trial; Chemotherapy; Lymphoma; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006656519,0.0004824359,0.002043002,0.0004013284,0.0001086949,0.00001975885,0.0004535768,0.0005197356,0.0001486778],"category_scores_gemma":[0.001780342,0.000351919,0.0002796036,0.001150619,0.0003329672,0.0000871521,0.0005809276,0.0002304317,0.0004464971],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006870906,"about_ca_system_score_gemma":0.000557246,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002695765,"about_ca_topic_score_gemma":0.0005837991,"domain_scores_codex":[0.9954899,0.0003849448,0.001400916,0.001042865,0.0006729266,0.001008455],"domain_scores_gemma":[0.9964503,0.001456201,0.0004713145,0.0009292169,0.0001990711,0.0004939109],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0489295,0.04119636,0.3990979,0.001534481,0.0009249682,0.0275306,0.003086466,0.0001461115,0.03232139,0.01893683,0.04674586,0.3795495],"study_design_scores_gemma":[0.08250049,0.01442177,0.8225558,0.0009042452,0.0002097708,0.0005242618,0.002071132,0.0009698194,0.0195415,0.001474816,0.05398391,0.0008424798],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818264,0.0003789559,0.00001049847,0.006767494,0.000565527,0.001809971,0.0001238545,0.0003235413,0.008193735],"genre_scores_gemma":[0.9951023,0.000188056,0.002235223,0.0005950976,0.00007596634,0.0006482776,0.0002049382,0.00004325894,0.0009068412],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4234579,"threshold_uncertainty_score":0.9998933,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0415212648976049,"score_gpt":0.3670687384005554,"score_spread":0.3255474735029505,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}